BGB-43395:在既往三线治疗的乳腺癌及实体瘤患者具初步疗效和良好安全性

山西证券
30 Jun

药物点评:BGB-43395 是一款百济神州自主研发的CDK4 抑制剂。BGB-43395 是CDK4 的高度选择性抑制剂,靶向控制细胞分裂的检查点蛋白以阻止癌细胞生长。相比CDK4/6 抑制剂哌柏西利、瑞波西利、阿贝西利及CDK4 抑制剂Atirmociclib,BGB-43395 展现出最高的CDK4 抑制性和选择性。BGB-43395具有潜在同类最佳血液学安全性特征,在既往接受过多线治疗的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10